Wire · opportunities
The mRNA technology behind Moderna's Covid vaccine reaches the flu
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 6 August 2026 · Fusion42 review
The FDA has approved Moderna's mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older, marking the first use of mRNA technology for influenza. The vaccine offers faster manufacturing and showed improved immune response and safety in clinical trials compared to existing flu vaccines.
This Wire brief sits within Fusion42's coverage of Biotech, and 12 sources have reported it between 6 Aug 2026 and 27 Aug 2026.
◆ ◆ The Wire takeaway
Older adult vaccine developers must now factor in the mRNA flu vaccine as a new competitor with faster update cycles and potentially better efficacy. You need to evaluate your product's positioning and development pace against Moderna’s mRNA flu vaccine technology.
◆ Coverage
12 sources · first reported 6 Aug 2026 · latest 27 Aug 2026
◆ Related on Wire
◆ Topics